Poster/Abstrakt: Does ColdZyme reduce upper respiratory tract infection (URTI) in endurance athletes, 3rd European Otolaryngology-ENT Surgery Conf, Oct 2018, London, UK
The incidence of URTI (Upper Airway Tract Infections) is higher than ‘normal’ in many athletes and such infections can compromise training and/or competition performance (Pyne et al., 2005). Strategies to reduce the risk of contracting these illnesses will be of benefit, and strategies to manage or treat ill athletes can optimise their recovery and limit the risks of spreading infection to others (i.e. team mates).
Design and Participants: Prospective, randomised, open label pilot study.
Thirty nine endurance-trained, competitive athletes were randomised to control (no treatment) or ColdZyme. They were monitored over the study period (December 2017 – February 2018) via training and illness symptom logs (Jackson common cold questionnaire). A total of 35 completed (n = 17 control; n = 18 ColdZyme).
Results and Discussion
At least one episode was recorded during the study period in 91% of all participants (94% control, 89% treatment). Fifty episodes were recorded in total over the study period with no difference between groups in the mean incidence rate (episodes/person: 1.4 ± 0.7 Control, 1.6 ± 0.9 Treatment, P = 0.266, all values are mean ± SD).
Episode duration was 10.9 ± 10.2 days in Control and 8.3 ± 6.3 days in Treatment (P = 0.098). When use compliance was examined, those in the treatment group with good compliance to the product instructions for use (IFU) were observed to have significantly lower (P = 0.038) episode duration (7.1 ± 6.6 days), but incidence was not different. This pilot study indicates that, when used correctly, ColdZyme can shorten the duration a common cold. The present findings with endurance athletes agree with those from a recent study (Clarsund et al., 2014) in which healthy adults were inoculated with Rhinovirus. Clarsund et al. (2014) observed a 54% reduction in illness duration with ColdZyme mouth spray treatment.